TY  - GEN
AU  - Bachiller, Mireia
AU  - Barceló-Genestar, Nina
AU  - Rodriguez-Garcia, Alba
AU  - Alserawan, Leticia
AU  - Dobaño-López, Cèlia
AU  - Giménez-Alejandre, Marta
AU  - Castellsagué, Joan
AU  - Colell, Salut
AU  - Otero-Mateo, Marc
AU  - Antoñana-Vildosola, Asier
AU  - Español-Rego, Marta
AU  - Ferruz, Noelia
AU  - Pascal, Mariona
AU  - Martín-Antonio, Beatriz
AU  - Anguela, Xavier M
AU  - Fillat, Cristina
AU  - Olesti, Eulàlia
AU  - Calvo, Gonzalo
AU  - Juan, Manel
AU  - Delgado, Julio
AU  - Pérez-Galán, Patricia
AU  - Urbano-Ispizua, Álvaro
AU  - Guedan, Sonia
PY  - 2025
DO  - 10.1016/j.ymthe.2024.11.028
SN  - 1525-0016
UR  - https://hdl.handle.net/20.500.12105/26052
AB  - CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given the...
LA  - eng
PB  - Cell Press
KW  - CAR-T cells
KW  - Co-transduction
KW  - Dual targeting
KW  - Lymphoma
KW  - Animals
KW  - Antigens, CD19
KW  - Cell Line, Tumor
KW  - Disease Models, Animal
KW  - Genetic Vectors
KW  - Humans
KW  - Immunotherapy, Adoptive
KW  - Lentivirus
KW  - Lymphoma, Non-Hodgkin
KW  - Mice
KW  - Receptors, Chimeric Antigen
KW  - T-Lymphocytes
KW  - Transduction, Genetic
KW  - Xenograft Model Antitumor Assays
TI  - ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.
TY  - research article
ER  -